Apr 23 |
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
|
Apr 9 |
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
|
Mar 29 |
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
|
Mar 29 |
Galectin Therapeutics GAAP EPS of -$0.74
|
Mar 29 |
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
|
Mar 21 |
Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
|
Mar 12 |
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
|
Feb 21 |
Retail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%
|
Nov 13 |
Galectin Therapeutics GAAP EPS of -$0.24
|
Nov 13 |
Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023
|